Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
about
Duloxetine versus other anti-depressive agents for depressionDuloxetine 60 mg once daily in the treatment of milder major depressive disorderDuloxetine in the treatment of major depressive disorder: an open-label studyDuloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label studySuperiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in JapanTreatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.Evaluation of efficacy of duloxetine in stress urinary incontinence in women.An improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol (D-142)The solute carrier 6 family of transportersChanges in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trialsIs duloxetine's effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trialsReview of duloxetine in the management of diabetic peripheral neuropathic pain.Emerging drugs for osteoarthritis.The role of duloxetine in the treatment of anxiety disorders.The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials.
P2860
Q24198808-302578A9-EF08-4F9A-A505-004B3F4C3BB7Q24546277-D15CEAEA-BF7B-4456-A512-B43BD9B978EDQ24565020-261E8FD4-6358-4A67-89B5-149A0CD54E58Q24801233-B6E289B0-706D-4571-B190-EE0D2D39628AQ33588319-C5C63512-17C5-4EC0-96BA-2AE60A5E9366Q33807834-05765628-CD5B-46A5-8C62-ADED3889E263Q34844161-69FA2947-9AC7-4B60-B169-2EE187675913Q35209813-B966BA82-3044-42C2-9F00-03C1223B5170Q36346899-063BC851-922E-4DE3-A59D-90E46D9B4CABQ36380157-B3B61A41-B813-4249-9EBE-32AC3D69A6A1Q36574971-88F82A1F-3BC2-45BD-B868-CBBBBEFBEECCQ36596907-EAEA20E7-6C5F-44C8-BCE6-B0EBA37F9665Q36931658-F5BA79DD-2594-436F-8BC6-1048D3B66CC8Q37062590-CF524175-3F9F-45B9-8706-3E3AD77F4881Q43051350-C8DFB9E4-4BCE-46A3-9BBB-CD90B3CA3F3B
P2860
Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@ast
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@en
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@nl
type
label
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@ast
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@en
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@nl
prefLabel
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@ast
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@en
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@nl
P1476
Dual serotonin and noradrenali ...... greater efficacy or just hype?
@en
P2093
David T Wong
Frank P Bymaster
P304
P356
10.1007/978-3-0348-8183-8_5
P577
2002-01-01T00:00:00Z